StockData
X4 Pharmaceuticals, Inc logo

X4 Pharmaceuticals, Inc (XFOR) stock

XFORNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Số liệu tài chính tới Q3 năm tài chính 2026, quý kết thúc ngày Sep 30, 2026Last filing: 10-Q on Nov 4, 2026Score 3/30
$3.09+0.26 (+9.19%)

Close on Nov 17, 2026Market cap $306.36MP/E –Yield –

X4 Pharmaceuticals gross margin

Gross margin is gross profit as a percentage of revenue.

X4 Pharmaceuticals's gross margin for the twelve months ending Sep 30, 2026 was 68.8%. For fiscal 2025 it was 11.4%, against 69.3% the year before.

Annual gross margin

PeriodPeriod endValueChange (pts)
FY2025Dec 31, 202511.4%−57.9
FY2024Dec 31, 202469.3%–

Quarterly gross margin

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange (pts)
Q3 FY2026Sep 30, 202681.7%+3.6
Q2 FY2026Jun 30, 202632.6%−48.2
Q1 FY2026Mar 31, 202676.1%+500.1
Q4 FY2025Dec 31, 202583.5%+3.6
Q3 FY2025Sep 30, 202578.1%+18.6
Q2 FY2025Jun 30, 202580.8%+28.4
Q1 FY2025Mar 31, 2025-424.0%–
Q4 FY2024Dec 31, 202479.9%–
Q3 FY2024Sep 30, 202459.5%–
Q2 FY2024Jun 30, 202452.4%–

More X4 Pharmaceuticals figures

See a number that looks wrong?